Pfizer
Home Hero Banner

Helping change the biologic landscape
with the cost-saving potential of biosimilars*

LEARN MORE

*IQVIA Institute for Human Data Science. Biosimilars in the United States 2023–2027:
Competition, Savings, and Sustainability. January 2023.

BIOSIMILARS MEAN

WHAT DO BIOSIMILARS MEAN FOR ME?

Learn how biosimilars may potentially expand treatment options to meet the growing demand for biologic therapies

LEARN MORE
PFIZER’S ROLE

WHAT IS PFIZER’S ROLE?

Explore more about how Pfizer builds on its experience with biologics through Pfizer biosimilars

LEARN MORE
IMPLEMENT BIOSIMILARS

HOW CAN I IMPLEMENT BIOSIMILARS?

Learn more about best practices for implementing potentially cost-saving biosimilars and the considerations for adopting them into practice

LEARN MORE

BIOSIMILARS BY
THE NUMBERS

Potential

100+

biologic products


Over 100 biologic products were expected to have lost patent or other protections by 2022, with additional products’ patents expiring in upcoming years

More

POTENTIAL savings

$181

billion


Biosimilars have been associated with $56 billion in savings since 2013 and are projected to produce an estimated $181 billion in savings from 2023 to 2027, based on a January 2023 IQVIA report

More

experience

15+

YEARS


Pfizer has more than 15 years of experience in the global biosimilars market

More
IMPLEMENT BIOSIMILARS

Considering implementing

biosimilars?

Learn more about the potential benefits of adopting a biosimilar

Learn More

FREQUENTLY ASKED QUESTIONS

How can I implement biosimilars?

There are 3 practical steps you can take to develop a biosimilar implementation strategy: preparation, implementation, and monitoring. Pfizer has provided resources that help you with these steps, covering operational enablement, informatics/IT, education, and monitoring. Review the “Downloadable Resources” page for materials, including electronic health record (EHR) biosimilar implementation support tools, informational videos, and much more.

What does the approval process for biosimilars involve?

Approved biosimilar medicines are required to have no clinically meaningful differences in terms of safety and efficacy from the relevant reference product. The approval is based on the totality of evidence from analytical, nonclinical, pharmacokinetic, and clinical studies.

What is extrapolation?

Extrapolation is a scientific and regulatory principle that refers to the approval of a biosimilar for use in an indication held by the reference product but not directly studied in a comparative clinical trial with a biosimilar. Extrapolation of efficacy and safety data from one indication to another may be considered if biosimilarity to the reference product has been shown by a comprehensive comparability program including safety, efficacy, and immunogenicity, and there is sufficient scientific justification for extrapolation. Extrapolation is not automatic and is considered only after biosimilarity is established based on the totality of evidence.

What are the potential benefits of biosimilars?

By potentially reducing costs while retaining safety, efficacy, and quality standards, biosimilars may be able to unlock resources that can be reinvested in things like improving patient care. Biosimilars may also help broaden treatment options for prescribers and patients to potentially improve overall health outcomes.

ALL FAQs
Close
Close

You are now leaving Pfizer

Links to sites outside of Pfizer are provided as a resource to the viewer. Pfizer accepts no responsibility for the content of linked sites.

Close

The information provided in this website is intended only for healthcare professionals in the United States. The products discussed may have different product labeling in different countries.

Close